← All trials
NCT04734652
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 4, 2021
- Primary completion
- Oct 4, 2023
- Completion date
- Oct 4, 2024
- First posted
- Feb 2, 2021
- Last posted
- Jul 28, 2021
- Enrollment
- 120
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Centre for the AIDS Programme of Research in South AfricaLead sponsor
- Centre for the AIDS Programme of Research in South AfricaOverall official - principal investigator
- Centre for the AIDS Programme of Research in South AfricaReponsible party - principal investigator
- Centre for the AIDS Programme of Research in South AfricaStudy director
- Medical Research Council, South AfricaCollaborator
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- Johns Hopkins UniversityCollaborator
- Johns Hopkins UniversityOverall official - principal investigator
- University of Cape TownCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.